StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
DMED.CN$0.04-10.00%
Fair $0.04+0.0%

DMED.CN

Diagnamed Holdings Corp.

Healthcare / Health Information ServicesCanadian Sec

$0.04

-0.00 (-10.00%)

Fairly Valued+0.0%Fair Value $0.04Fund rank 27/100 · Data gapFallback financials|
SA 13/F
F-Score: 1/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-444817.00 · quality 52.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

13/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is 3.1%, below the 5% threshold
Thesis & Journal · DMED.CNLocal privado en este navegador · Diagnamed Holdings Corp.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

311.7%

↑

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$0
$0$0

TradingView lightweight chart

DMED.CN price, volumen y niveles de valoración

Último $0.045Periodo -25.0%
Fair value: $0.045

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

0.24x

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $-1.4M · FCF $-336069.0

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts
MetricTTM
2025
2024
2023
2022
Income Statement
Net Income$-1.4M$-1.4M$-501057.00$-1.3M$-1.1M
EBITDA$-1.5M$-1.5M$-741243.00$-1.3M$-1.1M
EPS-0.02-0.02-0.01-0.02-0.01
Balance Sheet
Current Ratio0.380.38———
Cash Flow
Free Cash Flow$-336069.00$-336069.00$-444817.00$-1.1M$-787580.00
Returns
ROE311.7%311.7%189.0%-541.8%-90.9%
Valuation
P/B———13.26—
Growth & Yield
EPS Growth-100.0%-100.0%50.0%-34.6%—

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +12.5%

Total return

+12.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.02

Residual

+12.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+12.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.